EDITOR: | February 9th, 2016

Miraculins Appoints Ashwath Mehra to the Board of Directors

| February 09, 2016 | No Comments
image_pdfimage_print

Miraculins-200x125-1February 9, 2016 (Source) — Miraculins Inc. (TSXV: MOM) (the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces today, the appointment of Mr. Ashwath Mehra to the Company’s Board of Directors.

Mr. Mehra holds a BSc (Econ) from the London School of Economics and is currently the CEO of the Astor Group, an investment and advisory group of businesses. He has worked in the minerals industry for 22 years, starting his career with Philipp Brothers after which he spent 10 years with Glencore, where he was a senior partner and ran the Nickel and Cobalt Divisions. Mr. Mehra has substantial experience in mineral projects and project finance.

The Company also announces that Bill Roberts will be stepping down from the Board of Directors effective immediately, and that Mike Stasiuk will not seek re-election at the upcoming AGM which has been set for March 22, 2016.

“I want to thank both Bill Roberts and Mike Stasuik for their many years of faithful and dedicated service and significant contributions to the Company”, said Harry Bloomfield QC, Chairman of the Miraculins Board of Directors.

About Miraculins

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company’s Scout DS(R) device has been regulatory cleared in certain markets both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS(R) test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. For more information visit www.miraculins.com.

Miraculins Inc.
Christopher J. Moreau
President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Raj Shah

Editor:

Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>


Copyright © 2016 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Leave a Reply

Your email address will not be published. Required fields are marked *